3-[[4-[(2R)-1-(4-chlorophenyl)-1-(7-methylquinolin-4-yl)oxypentan-2-yl]benzoyl]amino]propanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-[[4-[(2R)-1-(4-chlorophenyl)-1-(7-methylquinolin-4-yl)oxypentan-2-yl]benzoyl]amino]propanoic acid
• 化学式: C₃₁H₃₁ClN₂O₄
• 分子量: 531.0
• InChiKey: LRBALMODBZKHHK-GOWJNXQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  88.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
  申请人：Kats-Kagan Roman

  公开号：US20110312911A1

  公开（公告）日：2011-12-22

  Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

  本文披露了胰高血糖素受体拮抗剂化合物。这些化合物对于治疗2型糖尿病及相关疾病非常有用。此外，还包括药物组合物和治疗方法。
• Methods For Treating Heart Failure Using Glucagon Receptor Antagonists
  申请人：REMD Biotherapeutics, Inc.

  公开号：US20170143673A1

  公开（公告）日：2017-05-25

  The present invention relates to methods for treating or preventing heart failure using a glucagon receptor antagonist or modulator. In various embodiments, the present invention relates to methods for treating post-myocardial infarction heart failure and lateral ventricular (LV) remodeling. In various embodiments, the present invention relates to methods for treating diabetic cardiomyopathy.
• US8809579B2
  申请人：——

  公开号：US8809579B2

  公开（公告）日：2014-08-19